assessment of therapeutic effect on post-CAR T-cell cases. The finding of enlarged lymph nodes by imaging study certainly raises concern of disease persistent or relapse.

Ethics Approval The study was approved by Fred Hutchinson Cancer Research Center's Ethics Board, approval numbers 1837, 9364

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of the this journal.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0642>

643

AUTOPSY REVIEW OF CHIMERIC-ANTIGEN RECEPTOR T CELL THERAPY: A SINGLE INSTITUTION EXPERIENCE

¹KiBeom Kwon, ²David Woolston, ²Alexandre Hirayama, ²Damian Green, ²David Maloney, ²Cameron Turtle, ²Cecilia Yeung*. ¹Seattle Cancer Care Alliance, Seattle, WA, USA; ²Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Background Our institution has treated over 300 patients with chimeric antigen receptor (CAR) T-cell immunotherapy (CAR T-cell therapy) since 2013. Phase I and II trials were primarily based on heavily treated patients with B cell acute lymphoblastic leukemia (B-ALL), aggressive diffuse large B cell lymphoma (DLBCL), and multiple myeloma (MM) who had failed multiple lines of prior chemotherapy and/or hematopoietic stem cell transplantation (HSCT). In these relapsed and/or refractory patients, CAR-T therapy resulted in complete remission in 93% of B-ALL, 60% of DLBCL, and ~80% of MM. Our Pathology Group at Fred Hutch have reviewed and diagnosed various patients with interesting relapse or complications as a result of CAR T-cell therapy. Here we present a retrospective review of autopsies from CAR T-cell therapy.

Methods A search for all autopsies conducted on patients from Seattle Cancer Care Alliance/University of Washington Medical Center was performed using the keywords 'CAR T' and 'Chimeric-antigen'. Our inclusion criteria were patients treated with CAR T-cell therapy. Pathology and clinical records were reviewed for cause of death, disease and treatment

timelines, microbiology data, cytokine levels, other pathology biopsies, and pertinent laboratory values. Histologic tissues were reviewed.

Results Twelve autopsies were performed since 2013. Patient characteristics and causes of death are summarized in table 1. The most common cause of death was due to infectious causes (n=6). Two patients (Patients 10 and 11) had cardiovascular related deaths. Six patients (Patients 1, 2, 6, 7, 10, 12) suffered from CRS in their post-infusion course, four of whom (Patients 1, 2, 7, 10) had CRS directly attributed as the cause of death. CRS was further complicated by immune effector cell-associated neurotoxicity syndrome (ICANS) in 5 patients (Patients 1, 5, 6, 7, and 12). CRS with ICANS was the second most common cause of death in patients treated with CAR T-cells. Three patients (Patients 1, 4, 9) had progression of disease that attributed to cause of death.

Conclusions CAR T-cell therapy is a highly effective treatment even for patients who have relapsed and/or refractory disease. Post-therapy complications range in severity and may be fatal in rare instances as in the patients summarized in this study. Infection, CRS with ICANS are the most common causes of death in our single institution study.

Ethics Approval The study was approved by Fred Hutchinson Cancer Research Center's Institutional Review Board, approval number 1837

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0643>

644

OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY

¹LeAnne Young*, ²Shanda Finnigan, ²Howard Streicher, ²Helen Chen, ²James Murray, ¹H Nida Sen, ²Elad Sharon. ¹National Eye Institute, Cleveland, OH, USA; ²National Cancer Institute, Bethesda, MD, USA

Background The programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are increasingly studied and are known to have unique inflammatory side effects due to non-specific immune system activation.¹ While rare, PD-1/PD-L1 inhibitors can cause ocular toxicities, including inflammatory eye disease.² However, these ocular adverse events are less well-studied.

Methods This was a retrospective review of two adverse event (AE) monitoring databases maintained by the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP), one of the largest public sponsors of clinical trials worldwide. One database (CTEP-AERS) is used for study sites to expeditiously report serious AEs for potential FDA review, while the other database (CDUS) is updated quarterly to reflect all the adverse events from the Phase 1 and Phase 2 trials in the CTEP network.

Results The two adverse event databases were queried for ocular adverse events up to May 19, 2020. A total of 331 adverse events from 259 patients were found. 73 patients (28%) were exposed to nivolumab, 117 patients (45%) were exposed to combination nivolumab and ipilimumab, 41 (16%) were exposed to pembrolizumab, 26 (10%) were exposed to atezolizumab, and 2 (0.8%) were exposed to durvalumab. 59 adverse events from 47 patients were reported by the study

Abstract 643 Table 1 Patient characteristics: age, sex, original diagnosis, CAR target, cause of death, and days post-CAR T-cell infusion at time of death

Patient code	Age at death	Gender	Original diagnosis	CAR target	Days post-CAR infusion upon death	Cause of Death
1	65	M	DLBCL	CD19	21	CRS/macrophage activation syndrome, endocarditis, septic shock with liver failure, and extensive diffuse large B cell lymphoma
2	48	F	ALL	CD19	3	C. Difficile pseudomembranous colitis and CRS
3	55	M	CLL/SLL	CD19	90	Aspergillus pneumonia
4	70	M	DLBCL	CD19	23 (post-1 st infusion) 9 (post-2 nd infusion)	Renal failure secondary to extensive involvement by diffuse large B cell lymphoma.
5	62	M	DLBCL	CD19	477 (post-1 st infusion) 436 (post-2 nd infusion)	Polymicrobial sepsis secondary to severe graft versus host disease from allogeneic stem cell transplant for treatment of refractory DLBCL
6	46	F	ALL	CD19	10	Clostridium septicum bacteremia
7	60	F	MM	BCMA	4/0 (post-1 st infusion) 35 (post-2 nd infusion)	Disseminated fungal infection and coagulase negative staphylococcus, secondary to pancytopenia and CRS
8	61	F	Follicular lymphoma	CD19	13	Hemorrhagic infarction of the brainstem.
9	67	M	MM	BCMA	198	Brain and Gross only autopsy - recurrent myeloma involving skin and scalp, periosteum of calvarium, dura, and leptomeninges
10	62	F	CLL	CD19	4	Cardiac arrhythmia in the setting of mitral valve annular calcinosis and cytokine release syndrome.
11	73	M	NHL-BCLU (Double Hit)	CD19	1439 (post-1 st infusion) 1390 post 2 nd infusion	Cardiac arrest from stress cardiomyopathy due to sepsis with right sided lung consolidations and maxillary sinusitis
12	65	M	DLBCL	CD19	47	E. coli bacteremia, coagulopathy

site as serious AEs and had more detailed clinical information available. Ocular AEs occurred within several months of initiating the study treatment (all ocular AEs: median 6 weeks, IQR 0–18, ocular AEs reported as serious: median 12 weeks, IQR 6–20). CTCAE grade for ocular AEs was generally mild to moderate (all ocular AEs: grade 1, IQR 1–2, ocular AEs reported as serious: grade 2, IQR 2–3). Clinical workup and treatment varied for the ocular AEs reported as serious. 30/47 patients (64%) receiving ophthalmologic evaluation. 16/47 (34%) of patients with serious ocular AEs had to delay or discontinue study drug treatment. However, 14/47 (30%) had improvement in their ocular AE and 16/47 patients (34%) had resolution of their ocular AE. The most common ocular AE treatments in our dataset were steroids (intravenous, oral, and steroid eye drops).

Conclusions Ocular adverse events are rare complications of PD-1/PD-L1 inhibitor therapy, can be severe enough to cause PD-1/PD-L1 treatment discontinuation or delay, but patients may not always be referred to eye specialists. Future PD-1/PD-L1 inhibitor studies would benefit from standardized plans for ophthalmologic evaluation of ocular toxicities.

REFERENCES

- Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. Longo DL, ed. *N Engl J Med*. 2018;**378**(2):158–168.
- Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy. *Retina* 2018;**38**(6):1063–1078.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0644>

645

PRECLINICAL DEVELOPMENT OF A NOVEL COLON-TARGETED THERAPEUTIC FOR THE TREATMENT OF IMMUNE CHECKPOINT INHIBITOR (ICI)-COLITIS

¹Nazli Dizman*, ²Milton L Greenberg, ²Andrew C Newman, ³Jonathan Skupsky, ⁴JoAnn Hsu, ⁴Zeynep Zengin, ⁴Nicholas Salgia, ⁴Luis Meza, ⁴Neal Chawla, ⁴Sabrina Salgia, ⁴Jasnoor Malhotra, ⁴Sumanta Pal. ¹Yale New Haven Hospital, New Haven, CT, USA; ²Vivreon Gastrosciences, Inc., San Diego, CA, USA; ³VA Long Beach, Long Beach, CA, USA; ⁴City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Background Immune Checkpoint Inhibitor (ICI) therapies have significantly improved overall survival in numerous cancers, but colitis has emerged as the most frequent dose-limiting toxicity associated with these therapies. Patients experiencing colitis side effects have to discontinue their cancer therapy to treat the colitis, which repositions life-threatening cancer. An ideal therapeutic would offer a colon-restricted approach to treating colitis side effects, while allowing patients to stay on their ICI therapy, an approach unavailable with currently approved therapies.

Methods To test this localized approach for the treatment of ICI-mediated colitis, we have developed a new chemical entity as a next-generation candidate therapeutic designed for oral administration. Permeability was tested in predictive epithelial monolayers and confirmed in rodent pharmacokinetic studies. We tested the drug in the preclinical adoptive transfer model for colitis. In this model, immunodeficient mice are hosts for adoptive transfer of naïve CD4+ T cells. In the absence of regulatory T cells, the transferred cells drive systemic inflammation and migrate to the colon, causing disease. Without treatment, these mice develop signs of colitis including weight loss, altered crypt architecture and infiltration of the lamina propria by week four. Furthermore, we developed a live

biopsy culture system to test drug effects on ICI-colitis patient biopsies obtained via colonoscopy.

Results In-vitro studies demonstrate that the drug has minimal toxicity and that it potently suppresses T cell proliferation and cytokine secretion. Permeability studies show a limited ability to cross the colonic mucosa restricting anti-inflammatory effects to sites of ulceration and active colitis. When colitis mice were given drug by oral gavage after colitis had developed, treated mice showed a significant increase in weight over controls and improved histological scores. Importantly, markers of systemic inflammation remained unchained, and the cancer-killing ability of the primary ICI therapy was preserved. Results of the live biopsy culture studies will be presented.

Conclusions These preliminary studies demonstrate that the candidate therapeutic has potential to become a novel next-generation oral therapy for ICI-colitis because it effectively limits leukocyte function in-vitro and in-vivo with minimal systemic absorption and minimal expected side effects. Given the favorable drug profile and the rapid growth of ICI therapies, our colon-restricted colitis therapeutic has the potential to improve outcomes in a large number of cancer patients. We anticipate commencing first-in-human studies in Q4 of 2021.

Acknowledgements None

Ethics Approval The study was approved by City of Hope Cancer Center Institutional Review Board with the approval number of 19304.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0645>

646

EVALUATING A PRECLINICAL MODEL OF CONTACT HYPERSENSITIVITY FOR SKIN IMMUNE CHECKPOINT TOXICITY

¹Barbara Ma*, ²Abhinav Jaiswal, ²K Sanjana Devi, ²Qingrong Huang, ²Joy Hsu, ²Yong Liu, ²Niroshana Anandasabapathy. ¹New York Presbyterian/Weill Cornell Medicine, New York, USA; ²Weill Cornell Medicine, New York, NY, USA

Background Immune checkpoint inhibitors (ICIs) are limited by the high incidence of immune-related adverse events (irAEs) occurring in up to 40% of solid tumor patients on anti-PD-1 monotherapy^{1,2} and 72% in anti-CTLA-4/anti-PD-1 combination.^{3,4} These toxicities can cause treatment cessation, hospitalization and even death.^{5–7} IrAEs are variable in severity, timing, onset, and remain poorly understood. Amongst the different toxicities, skin irAEs are most frequent, occur the earliest, and are correlated with a positive prognosis.^{4,8} However, there is a lack of preclinical models to study checkpoint toxicity. We evaluated a murine model of allergic contact dermatitis (contact hypersensitivity to 2,4-dinitrofluorobenzene) that is mediated by CD8+ T cells to gain a mechanistic understanding of skin checkpoint toxicity.

Methods C57BL/6 mice (n = 5 per group) were sensitized epicutaneously on shaved flank with hapten 0.5% DNFB on day -5 and elicited on their ears with DNFB on day 0. Starting four weeks later, mice were treated with either anti-programmed cell death protein (PD-1) or isotype. At the time of the first recall challenge only, mice were given either anti-PD-1 or isotype. Mice received subsequent rechallenges with DNFB to the ears and ear swelling was measured at various time points. Mice were depleted of circulating or skin CD8+